BNTX BioNTech SE ADRs

BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$163.36  +0.36 (0.22%)
As of 05/23/2022 15:59:59 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  10/10/2019
Outstanding shares:  243,019,216
Average volume:  1,405,678
Market cap:   $40,795,635,790
Current dividend yield:  1.26%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BK6H543

---

Valuation   (See tab for details)

---

PE ratio:   3.12
PB ratio:   2.49
PS ratio:   1.66
Return on equity:   80.85%
Net income %:   55.20%